News from ABBVIE A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jul 02, 2015, 08:00 ET

AbbVie to Host Second-Quarter Earnings Conference Call

 AbbVie (NYSE: ABBV) will announce its second-quarter 2015 financial results on Friday, July 24, 2015, before the market opens. AbbVie will...

Jul 01, 2015, 10:30 ET

HUMIRA (Adalimumabe) da AbbVie é aprovado no Brasil para tratamento de Espondiloartrite Axial Não Radiográfica

- Este é o primeiro e único medicamento aprovado para tratamento de espondiloartrite axial não radiográfica severa em...

Jun 29, 2015, 14:47 ET

AbbVie anuncia resultados de Fase 3b de estudo com pacientes crônicos com Hepatite C, Genótipo 1b, e Cirrose Hepática Compensada

- 100 % dos pacientes mantiveram resposta virológica sustentada após 12 semanas de tratamento com VIEKIRA PAK (comprimidos de...

Jun 29, 2015, 07:00 ET

AbbVie's HOLKIRA™ PAK Now Reimbursed in Ontario

- Common Drug Review grants positive recommendation for HOLKIRA PAK - Ontario is the second province in Canada to reimburse HOLKIRA...

Jun 24, 2015, 06:00 ET

AbbVie Announces New Phase 3b Results in Genotype 1b Chronic Hepatitis C Patients with Compensated Liver Cirrhosis

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced TURQUOISE-III study results demonstrating 100 percent (n=60/60) sustained...

Jun 18, 2015, 17:01 ET

AbbVie Declares Quarterly Dividend

 The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.51 per share.  The cash dividend is payable...

Jun 12, 2015, 09:00 ET

AbbVie to Present Data from Studies of DUOPA® (carbidopa and levodopa) Enteral Suspension in Advanced Parkinson's Disease During the International Congress of Parkinson's Disease and Movement Disorders

 AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced it will present data from studies of DUOPA® (carbidopa and...

Jun 12, 2015, 02:30 ET

Phase 1b Study of Investigational Treatment Venetoclax with Rituximab Shows Clinical Response in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

 AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced updated results of a Phase 1b study that showed patients with...

Jun 08, 2015, 08:00 ET
AbbVie’s Week of Possibilities shows how #AbbVieGivesBack

AbbVie Mobilizes 3,100 Employees for Week of Service Projects to Transform Schools and Communities Globally

 AbbVie, a global biopharmaceutical company, today launched its second annual Week of Possibilities volunteer program, with 3,100 employees...

Jun 08, 2015, 08:00 ET

AbbVie to Present Data from Studies of the Company's Oncology Pipeline at the 20th European Hematology Association Annual Congress

 AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced it will present data on its investigational hematological malignancy...

Jun 05, 2015, 16:00 ET

AbbVie to Present at Goldman Sachs 36th Annual Global Healthcare Conference

 AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 36th Annual Global Healthcare Conference on Tuesday, June 9, 2015. Bill Chase,...

Jun 04, 2015, 07:00 ET

AbbVie's Research in Immunology to be Featured at the European League Against Rheumatism Annual Congress (EULAR) 2015

 AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced that data from more than 30 abstracts on HUMIRA® (adalimumab),...

Jun 01, 2015, 12:22 ET

AbbVie to Present at Jefferies 2015 Healthcare Conference

 AbbVie (NYSE: ABBV) will participate in the Jefferies 2015 Healthcare Conference on Thursday, June 4, 2015. Richard A. Gonzalez, chairman and...

Jun 01, 2015, 08:00 ET

AbbVie Presents Phase 2 Results from Study of Investigational Medicine Veliparib in Patients with Non-Small Cell Lung Cancer at the American Society of Clinical Oncology Annual Meeting

AbbVie (NYSE:ABBV), a global biopharmaceutical company, today announced findings from a Phase 2 study of the investigational medicine veliparib...

May 31, 2015, 08:00 ET

AbbVie Presents Results from Phase 1 Studies of Investigational Compound Venetoclax in Patients with Multiple Myeloma at the American Society of Clinical Oncology Annual Meeting

 AbbVie (NYSE:ABBV), a global biopharmaceutical company, today announced that results from a Phase 1b trial of investigational venetoclax, a...

May 28, 2015, 13:02 ET

AbbVie apresenta estudos sobre novos tratamentos em pesquisa para câncer no 51o encontro da Sociedade Americana de Oncologia Clínica (ASCO)

No 51o Encontro Anual da Sociedade Americana de Oncologia Clínica (ASCO),  29 de maio a 2 de junho, Chicago, AbbVie apresenta 17...

May 26, 2015, 19:00 ET

AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis

 AbbVie (NYSE: ABBV) presented new results from the Phase 3 GIFT-I study of its investigational, all-oral, interferon (IFN)- and ribavirin...

May 26, 2015, 08:30 ET

AbbVie Completes Acquisition of Pharmacyclics

 AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that it has completed the acquisition of Pharmacyclics, Inc....

May 22, 2015, 08:00 ET

AbbVie Announces Expiration of Hart-Scott-Rodino Waiting Period for AbbVie's Acquisition of Pharmacyclics

AbbVie (NYSE: ABBV) announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 for AbbVie's purchase of...

May 21, 2015, 08:00 ET

AbbVie Announces Offer Consideration for Acquisition of Pharmacyclics

 AbbVie (NYSE: ABBV) announced today the per share offer consideration amounts pursuant to its previously announced offer to acquire each...